Death domain containing receptor 4 antibody and methods
View Patent ↗The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.
1. A method of inducing apoptosis of a DR4-expressing cell comprising contacting said cell with an alpha interferon and an agonist antibody which binds to a polypeptide selected from the group consisting of:
(a) amino acids 24 to 238 of SEQ ID NO:2; and
(b) the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853.
2. The method of claim 1 , wherein said antibody binds to a polypeptide consisting of amino acids 24 to 238 of SEQ ID NO:2.
3. The method of claim 1 , wherein said antibody binds to a polypeptide consisting of the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853.
4. The method of claim 1 , wherein said antibody is a monoclonal antibody.
5. The method of claim 1 , wherein said antibody is a polyclonal antibody.
6. The method of claim 1 , wherein said antibody is a chimeric antibody.
7. The method of claim 1 , wherein said antibody is a human antibody.
8. The method of claim 1 , wherein said antibody is a humanized antibody.
9. The method of claim 1 , wherein said antibody is a single-chain Fv antibody.
10. The method of claim 1 , wherein said antibody is an Fab antibody fragment.
11. The method of claim 1 , which is in vitro.
12. The method of claim 1 , which is in vivo.
13. The method of claim 1 , wherein said cell is contacted by said antibody and said alpha interferon simultaneously.
14. The method of claim 1 , wherein said cell is contacted by said antibody and said alpha interferon sequentially.
15. The method of claim 1 , wherein said alpha interferon is selected from the group consisting of:
(a) interferon alpha 2a; and
(b) interferon alpha 2b.
16. The method of claim 1 , wherein said cell is a cancer cell.
17. The method of claim 16 , wherein said cancer cell is a hepatoma cell.